Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States.
| Autor: | Schabert V; Independent, Sarajevo, Bosnia and Herzegovina., Shah S; Evidera Inc, Waltham, MD, USA., Holmgren U; AstraZeneca plc, Gothenburg, Sweden., Cabrera C; BioPharmaceuticals Medical, AstraZeneca, KC6 SE-431 83 Mölndal, Gothenburg, Sweden. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Therapeutic advances in respiratory disease [Ther Adv Respir Dis] 2021 Jan-Dec; Vol. 15, pp. 17534666211001018. |
| DOI: | 10.1177/17534666211001018 |
| Abstrakt: | Background: Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend triple therapy (TT) for chronic obstructive pulmonary disease (COPD) patients based on severity. TT utilization by severity is infrequently studied in real-world settings and may deviate significantly from current clinical recommendations. This study describes prescribing pathways to TT among patients with COPD in the United States. Methods: This study analyzed Geisinger Health System electronic medical records from 1 January 2004 to 30 November 2016. Two retrospective cohorts of COPD patients were included: (1) incident COPD, and (2) incident TT users. COPD treatment patterns, including time to TT, were summarized. Time to TT was estimated using Kaplan-Meier methods. Predictors of the relative hazard for TT among incident COPD patients were estimated using Cox proportional hazards regressions. Results: Incident COPD and TT cohorts included 57,141 and 8173 patients, respectively. TT was used by 9.6% of incident COPD patients. In the year before TT, 34.3% of incident TT patients received treatment combinations recommended before TT according to GOLD recommendations, which mainly included: long-acting muscarinic antagonists (LAMAs), long-acting beta agonists (LABAs) + LAMAs, and inhaled corticosteroids + LABAs. Among incident TT patients, median time from COPD diagnosis to TT exceeded 2 years. The hazard for TT over time was associated with lower forced expiratory volume in 1 s values, more frequent exacerbations, current/previous smoking, and comorbid lung conditions such as pulmonary vascular disease, acute respiratory failure, and lung cancer. About 15-20% of the incident TT patients stepped down to a one- or two-drug regimen. Median time to TT discontinuation or step-down were 2 and 9 months, respectively. Conclusion: The study has revealed discrepancies in the treatment of COPD patients between GOLD guidelines and actual clinical practices in the United States. Pathways to TT differed from recommended therapy regimes. Further studies are needed to understand barriers to the use of guideline-recommended TTs by healthcare providers. The reviews of this paper are available via the supplemental material section. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|